Who Benefits from P.C.I. in Ischemic C.M.? 10/06/25

Welcome to Cardiology Today – Recorded October 06, 2025. This episode summarizes 4 key cardiology studies on topics like percutaneous coronary intervention and left anterior descending artery. Key takeaway: Who Benefits from P.C.I. in Ischemic C.M.?. Article Links: Article 1: Impact of Coronary Hypoperfusion During Agonal Phase on Outcomes Following Donation After Circulatory Death Heart Transplantation. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation) Article 2: Predicting LVEF after PCI and Its Effect on Clinical Outcomes in Patients with Stable Ischemic Cardiomyopathy and LVEF≤50. (The American journal of cardiology) Article 3: Association of myocardial bridging and LAD length with Takotsubo syndrome: A MINOCA cross-sectional study. (International journal of cardiology) Article 4: Effect of Opt-in versus Opt-out Framing on Trial Recruitment: A Study Within A Trial of the GAMEPAD Randomized Trial. (American heart journal) Full episode page: https://podcast.explainheart.com/podcast/who-benefits-from-p-c-i-in-ischemic-c-m-10-06-25/ Featured Articles Article 1: Impact of Coronary Hypoperfusion During Agonal Phase on Outcomes Following Donation After Circulatory Death Heart Transplantation. Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41047011 Summary: This study in The Journal of Heart and Lung Transplantation is evaluating the impact of coronary hypoperfusion during the agonal phase on outcomes following donation after circulatory death heart transplantation. Researchers queried the U.N.O.S. registry to analyze adult recipients of isolated D.C.D. heart transplants between 2019 and 2023. They are stratifying recipients based on the proportion of the agonal phase with coronary hypoperfusion, defined as diastolic blood pressure below 40 M.M. H.G., to determine its effect on transplant success and inform donor management. Article 2: Predicting LVEF after PCI and Its Effect on Clinical Outcomes in Patients with Stable Ischemic Cardiomyopathy and LVEF≤50. Journal: The American journal of cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41046997 Summary: This study in The American Journal of Cardiology aims to identify specific subgroups of stable ischemic cardiomyopathy patients who experience left ventricular ejection fraction improvement and clinical benefit from percutaneous coronary intervention. While P.C.I. typically does not improve L.V.E.F. or heart failure outcomes for most S.I.C.M. patients, this research is screening a cohort of over 1700 patients with a baseline L.V.E.F. less than or equal to 50 percent. The methodology focuses on patients with significant target vessel involvement and a predominance of viable myocardium over scar to pinpoint potential responders to revascularization. Article 3: Association of myocardial bridging and LAD length with Takotsubo syndrome: A MINOCA cross-sectional study. Journal: International journal of cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41046874 Summary: This cross-sectional study published in the International Journal of Cardiology investigates the potential association of myocardial bridging and left anterior descending artery length with Takotsubo syndrome. Leveraging a well-characterized MINOCA cohort, the researchers aim to assess if these specific anatomical features contribute to T.T.S., which is characterized by transient left ventricular dysfunction often triggered by stress. This research seeks to clarify the underlying pathophysiology of Takotsubo syndrome. Article 4: Effect of Opt-in versus Opt-out Framing on Trial Recruitment: A Study Within A Trial of the GAMEPAD Randomized Trial. Journal: American heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41046994 Summary: This study within a trial, published in the American Heart Journal, is investigating the effect of opt-in versus opt-out recruitment strategies on participant enrollment in randomized clinical trials. Embedded within the G.A.M.E.P.A.D. trial for peripheral artery disease patients, this research randomized eligible individuals to receive either an opt-in invitation requiring active consent or an opt-out invitation implying automatic enrollment unless declined. The study aims to determine which outreach strategy yields a higher enrollment fraction and improves protocol completion, potentially optimizing future clinical trial efficiency. Transcript Today’s date is October 06, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Impact of Coronary Hypoperfusion During Agonal Phase on Outcomes Following Donation After Circulatory Death Heart Transplantation. This study in The Journal of Heart and Lung Transplantation is evaluating the impact of coronary hypoperfusion during the agonal phase on outcomes following donation after circulatory death heart transplantation. Researchers queried the U.N.O.S. registry to analyze adult recipients of isolated D.C.D. heart transplants between 2019 and 2023. They are stratifying recipients based on the proportion of the agonal phase with coronary hypoperfusion, defined as diastolic blood pressure below 40 M.M. H.G., to determine its effect on transplant success and inform donor management. Article number two. Predicting LVEF after PCI and Its Effect on Clinical Outcomes in Patients with Stable Ischemic Cardiomyopathy and LVEF≤50. This study in The American Journal of Cardiology aims to identify specific subgroups of stable ischemic cardiomyopathy patients who experience left ventricular ejection fraction improvement and clinical benefit from percutaneous coronary intervention. While P.C.I. typically does not improve L.V.E.F. or heart failure outcomes for most S.I.C.M. patients, this research is screening a cohort of over 1700 patients with a baseline L.V.E.F. less than or equal to 50 percent. The methodology focuses on patients with significant target vessel involvement and a predominance of viable myocardium over scar to pinpoint potential responders to revascularization. Article number three. Association of myocardial bridging and LAD length with Takotsubo syndrome: A MINOCA cross-sectional study. This cross-sectional study published in the International Journal of Cardiology investigates the potential association of myocardial bridging and left anterior descending artery length with Takotsubo syndrome. Leveraging a well-characterized MINOCA cohort, the researchers aim to assess if these specific anatomical features contribute to T.T.S., which is characterized by transient left ventricular dysfunction often triggered by stress. This research seeks to clarify the underlying pathophysiology of Takotsubo syndrome. Article number four. Effect of Opt-in versus Opt-out Framing on Trial Recruitment: A Study Within A Trial of the GAMEPAD Randomized Trial. This study within a trial, published in the American Heart Journal, is investigating the effect of opt-in versus opt-out recruitment strategies on participant enrollment in randomized clinical trials. Embedded within the G.A.M.E.P.A.D. trial for peripheral artery disease patients, this research randomized eligible individuals to receive either an opt-in invitation requiring active consent or an opt-out invitation implying automatic enrollment unless declined. The study aims to determine which outreach strategy yields a higher enrollment fraction and improves protocol completion, potentially optimizing future clinical trial efficiency. Thank you for listening. Don’t forget to subscribe. Keywords percutaneous coronary intervention, left anterior descending artery, opt-out consent, diastolic blood pressure, heart failure outcomes, Myocardial bridging, left ventricular dysfunction, myocardial viability, Stable ischemic cardiomyopathy, heart transplantation, MINOCA, Donation after circulatory death, Takotsubo syndrome, opt-in consent, left ventricular ejection fraction, coronary hypoperfusion, randomized clinical trial, Clinical trial recruitment, peripheral artery disease, agonal phase. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post Who Benefits from P.C.I. in Ischemic C.M.? 10/06/25 first appeared on Cardiology Today.